Navigation Links
ViroPharma Receives Complete Response Letter for Cinryze(TM) Supplemental Biologics License Application for Acute Treatment of Hereditary Angioedema
Date:6/4/2009

ials. Severe hypersensitivity reactions may occur. Thrombotic events have occurred in patients receiving high dose off-label C1 inhibitor therapy well above the approved treatment dosage regimen. With any blood or plasma derived product, there may be a risk of transmission of infectious agents, e.g. viruses and, theoretically, the CJD agent. The risk has been reduced by screening patients for prior exposure to certain virus infections and by manufacturing steps to reduce the risk of viral transmission including pasteurization and nanofiltration.

Cinryze is for intravenous use only. A dose of 1000 Units of Cinryze can be administered every 3 or 4 days for routine prophylaxis against angioedema attacks in HAE patients. Cinryze is administered at an injection rate of 1 mL per minute.

About Hereditary Angioedema (HAE)

HAE is a rare, severely debilitating, life-threatening genetic disorder caused by a deficiency of C1 inhibitor, a human plasma protein. This condition is the result of a defect in the gene controlling the synthesis of C1 inhibitor. C1 inhibitor maintains the natural regulation of the contact, complement, and fibrinolytic systems, that when left unrestricted, can initiate or perpetuate an attack by consuming the already low levels of endogenous C1 inhibitor in HAE patients. Patients with C1 inhibitor deficiency experience recurrent, unpredictable, debilitating, and potentially life threatening attacks of inflammation affecting the larynx, abdomen, face, extremities and urogenital tract. Patients with HAE experience approximately 20 to 100 days of incapacitation per year. There are estimated to be at least 6,000 people with HAE in the United States.

For more information on HAE, visit the U.S. HAE Association's website at: www.haea.org.

About ViroPharma Incorporated

ViroPharma Incorporated is a biopharmaceu
'/>"/>

SOURCE ViroPharma Incorporated
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. ViroPharma to Present at Two June Healthcare Conferences
2. ViroPharma Incorporated Honored by the National Organization for Rare Disorders
3. ViroPharma Incorporated Reports First Quarter 2009 Financial Results
4. ViroPharma to Release 2009 First Quarter Financial Results on April 29, 2009
5. ViroPharma Improves Financial Position Through Repurchase of $45 Million Principal Amount of Senior Convertible Notes
6. ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results
7. ViroPharma to Present at Three November Healthcare Conferences
8. ViroPharma Enhances Leadership to Support Global Growth and Expanding Business
9. ViroPharma to Release 2008 Third Quarter Financial Results on October 29, 2008
10. ViroPharma to Present at Three October Healthcare Conferences
11. ViroPharma to Present at Three September Healthcare Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... , Dec. 23, 2014  NeuroLifeSciences announced today ... in children with attention deficit/hyperactivity disorder published in ... The paper, titled "Pilot Phase 2 ... ( Konofal et al, Drug Des Devel ... shows that mazindol might be an effective, well-tolerated, ...
(Date:12/22/2014)... ROCKVILLE, Md. , Dec. 22, 2014 ... MKT: SYN), a developer of pathogen-specific therapies ... focus on protecting the microbiome, today announced ... a Phase 1a clinical trial of SYN-004, ... the prevention of Clostridium difficile (C. ...
(Date:12/22/2014)... , Dec. 22, 2014  Alternative Energy ... that it has signed a letter of intent ... has developed and patented a nanotechnology-based development platform ... products that enable rapid on-site collection and testing ... and health issues in an immediate, non-invasive and ...
(Date:12/22/2014)... 2014  ( www.competitivehealth.com ) — Competitive Health is ... review and advocacy service, has signed an agreement to ... discount health services marketplace. 63% of Americans ... they expected to pay. As part of an ongoing ... Savings is pleased to offer medical bill review and ...
Breaking Biology Technology:Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 2Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 2Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 4Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 5ALNE Announces Intention To Acquire BioTechPharma 2WellCard Savings Announces CoPatient Medical Bill Review Service for Members 2
... Mylan Inc. (Nasdaq: MYL ) today announced that ... $1.25 million to support two prominent West Virginia cultural institutions ... West Virginia and the State of West Virginia Division of ... a member of Mylan Charitable Foundation,s board of directors said ...
... Encorium Group, Inc. (Nasdaq:  ENCO), (the "Company"), a ... studies in over 30 countries for many of ... announced that, on October 20, 2010, it received ... "Panel") has determined to delist the Company,s securities ...
... but it has become even harder in recent years the ... slow it down anymore. Reporting their findings in the journal ... closer to understanding why not, and how future treatments can defeat ... drugs, amantadine and rimantadine, are no longer recommended by the CDC ...
Cached Biology Technology:Mylan and Mylan Charitable Foundation Award a Collective $1.25 Million to Prominent West Virginia Cultural Institutions 2Encorium Announces NASDAQ Panel Decision to Delist Common Stock; Announces Changes to its Board of Directors 2Encorium Announces NASDAQ Panel Decision to Delist Common Stock; Announces Changes to its Board of Directors 3Encorium Announces NASDAQ Panel Decision to Delist Common Stock; Announces Changes to its Board of Directors 4Putting a bull's-eye on the flu: Detailing influenza's structure for drug targeting 2
(Date:12/17/2014)... Dec. 15, 2014 Research and Markets ... of the "Samsung Galaxy S5 - Home ... to their offering. ... different sensing technology than the iPhone 5S, Samsung ... in its product. The Galaxy S5 ...
(Date:12/17/2014)... , Dec. 16, 2014 Valencell, a leader ... PerformTek biometric technology to industry leaders such as Intel, ... clinically validated, biometric wearable products. These products will be ... Las Vegas . ... accurate, flexible and robust – with the clinical data ...
(Date:12/15/2014)... DUBLIN , Dec. 12, 2014 Research ... announced the addition of the "Global Facial ... http://photos.prnewswire.com/prnh/20130307/600769 ... the identification of individuals. Facial recognition system measures ... as nose, jaw edges, mouth, and the distance ...
Breaking Biology News(10 mins):Samsung Galaxy S5 - Home Button Synaptics Fingerprint Sensor Technology Analysis 2Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3
... traditional Dutch landscapes says Dutch researcher Evelien van ... cultural historic value will disappear unless specific agricultural ... both considerable investments and sufficient legislation from the ... possible improvements to rules and policy programmes for ...
... - In pursuing cleaner energy there is such a thing ... be considered too green. In a paper in a special ... (OSA) open-access journal, scientists at the University of California, Berkeley ... researchers explain a way to genetically modify the tiny organisms, ...
... the Fisheries , an archive of oral histories ... and families that rely on them, documents the ... Great Lakes environments and living marine resources. ... Silva of NOAA,s National Marine Fisheries Service have ...
Cached Biology News:Traditional Dutch landscape under threat 2Engineering algae to make fuel instead of sugar 2Human connection to our nation's fisheries comes alive through oral history project 2Human connection to our nation's fisheries comes alive through oral history project 3
... a new tuning and calibration standard for ... Accumix is a lyophilized 7-peptide standard ... both tuning and calibration of ion trap ... transform mass spectrometers. Direct infusion of ...
Determin interaction of your protein with Echelons lipids...
... N-Dodecyl-N,N-(dimethylammonio)butyrate White crystalline solid. HYGROSCOPIC. ... DDMAU (Cat. No. 252005) but differing in ... efficient for the extraction of mycoplasma membrane ... Purity: ≥98% by TLC. Soluble in ...
... The Eppendorf Reference Series 2000 Pipette ... smooth stroke, a compact and robust design, ... button is used to operate the measuring ... the tip. Product features:Eppendorf "pipette/tip" system ensures ...
Biology Products: